Last updated: October 19, 2026
Purpose and Scope
SemaGLP publishes content about semaglutide and related medications for readers researching U.S. drug labels, legitimate prescription access, payment terms and evidence-based comparisons. This policy governs how we aim to research, draft, revise and correct information. It does not replace individual clinical judgment.
Editorial independence requires that the truth of a drug claim not depend on whether a third-party pharmacy, platform or manufacturer might benefit from a link.
Core Editorial Principles
Our articles aim to be accurate, specific, dated where needed, proportionate to the evidence, useful to readers and transparent about limitations. A semaglutide comparison should distinguish molecule, brand, formulation, FDA indication, study population, and purchasing question rather than using them as synonyms.
We avoid fabricated prices, nationwide inventory assertions, unsupported pharmacy recommendations, guaranteed telehealth prescriptions or unverified generic approvals. Commercial headings must not override contraindications or important limitations.
Evidence Hierarchy by Claim Type
For U.S. approval, product identity and labeled safety, we favor FDA approval records and FDA prescribing information, with DailyMed as a label resource. For generic equivalence, FDA application and Orange Book records are central. For study results, we examine trial methods, comparator doses, outcomes and populations; for Medicare or Medicaid we use the applicable CMS or state program guidance.
Manufacturer announcements may document a launch, device format or program offer, but they do not establish a clinician’s recommendation, current retail stock or a drug’s FDA approval in another country.
| Claim type | Preferred source | Important limitation |
|---|---|---|
| FDA-approved indications | Current FDA prescribing information / Drugs@FDA | Specific route, product, indication and age group |
| Drug safety and interactions | Product-specific FDA label and major safety notices | Not every formulation has identical wording |
| Generic marketing approval | FDA NDA/ANDA and Orange Book records | NDC existence alone is not approval |
| Head-to-head effectiveness | Original randomized study and methods | Specified trial arms are not general dose equivalents |
| Online pharmacy legitimacy | FDA BeSafeRx and state board records | A search result is not license confirmation |
| Insurance and savings | CMS, state program, plan or manufacturer terms | Member-specific eligibility and dates matter |
| Indian brand and manufacturer roles | Dated CDSCO or primary company disclosures | India approval does not equal FDA approval |
How We Treat Brands and Formulations
Ozempic, Wegovy, legacy Rybelsus and foreign semaglutide brands cannot be flattened into one generic drug listing. Tablets and injections often have different labeled directions, strengths and additional indications. Our articles identify the product first and only then discuss practical access or studies.
Any major U.S. oral semaglutide branding transition must be dated. A strength number on one formula does not permit a milligram-for-milligram conversion with another product.
Clinical Evidence and Comparisons
Randomized studies can be useful but require careful interpretation. SUSTAIN, STEP, SURPASS and SURMOUNT trials examined defined doses, populations, comparators and time frames. A head-to-head finding from specified injections cannot be generalized to an oral presentation, a later higher-dose device or a different diagnosis.
When no direct comparison exists, we distinguish separate trials from comparative proof. We do not create cross-trial rankings by subtracting published mean outcomes from unrelated populations.
Safety Information
Safety statements should identify the relevant label and distinguish common adverse reactions from important warnings, contraindications and reasons to seek care. The boxed warning for semaglutide products and related precautions must be handled as actual labeling, not a one-line alarm or reassurance.
We do not recommend altering treatment, combining GLP-1 products, converting injection doses or buying a drug without appropriate medical assessment.
Compounded, Foreign and Generic Product Claims
Compounded preparations are not FDA-approved finished medicines, and pharmacy compounding has distinct legal requirements. Foreign-market approval, including in India, is not U.S. FDA marketing authorization; an Indian product brand should not be misrepresented as an approved American generic.
Where companies describe co-marketing deals, we distinguish the formulation developer, manufacturer, supply partner and marketer. An FDA warning letter about a seller is not automatically a finding about a manufacturer or proof that a foreign-market brand is counterfeit.
Prescription and Pharmacy Information
A legitimate U.S. Rx product requires an appropriate prescription and licensed dispensing. Remote consultation services, price-comparison platforms, manufacturers and pharmacies perform different roles. Content must not present a referral as a direct endorsement of pharmacy legitimacy.
We refer readers to independent licensing checks and disclose material uncertainty about current availability, delivery and program conditions.
Evergreen Prices and Insurance
Cost guides explain list versus retail cash, self-pay terms versus insured copays, quantity and package differences, program expiration, plan restrictions and ancillary clinician fees. We do not pretend a posted promotional rate is a permanent national retail price.
For coverage, the exact product, diagnosis and payer determine relevance. A published Medicare demonstration rule does not automatically apply to commercial insurance or state Medicaid.
Editorial Checking Versus Professional Medical Review
Editorial checking includes verifying citation fit, dates, grammar, product names, links, and whether the page fulfills a distinct informational intent. Clinical review requires qualified medical expertise to evaluate the medical meaning and safety of the advice. One cannot be relabeled as the other.
When a named professional reviews specific content, attribution should be accurate and independently supportable. The reviewer standards and process pages explain the distinction.
Corrections and Updating
We aim to correct verified factual mistakes, misleading omissions and materially outdated regulatory information. Appropriate corrections may include changing a strength, amending a claim, replacing a broken source or clarifying that a program offer expired.
Readers may report a problem via Contact SemaGLP with the affected URL and relevant evidence. We review submissions according to their substantiation; sending a message does not guarantee a particular edit or response.
Advertising, Affiliates and Editorial Separation
SemaGLP may receive compensation when readers follow qualifying third-party referrals. Sponsored links should be distinguished from editorial links and marked appropriately. Such relationships must not be portrayed as clinical endorsement or proof that an item is safe, approved, stocked or covered.
We do not accept commercial terms as substitutes for independent product labeling, legitimate prescriber decisions or current official documentation.